The drug and vaccine maker reported a $248 million loss, compared with a $2.91 billion profit a year earlier, while higher sales in its cancer business helped lift overall revenue.
Pfizer swung to a second-quarter loss even as revenue increased, with growth in its oncology business cushioning declines in its Covid-19 products. The drug and vaccine maker reported a loss of $248 million, or 4 cents a share, on Tuesday, versus a profit of $2.91 billion, or 51 cents a share, in the same period a year earlier.